Xenetic Biosciences (NASDAQ:XBIO) Announces Earnings Results

Xenetic Biosciences (NASDAQ:XBIO) issued its quarterly earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.48), Zacks reports. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%.

Xenetic Biosciences Stock Down 5.7 %

Shares of Xenetic Biosciences stock traded down $0.21 on Tuesday, hitting $3.46. The stock had a trading volume of 13,751 shares, compared to its average volume of 12,669. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20. The stock has a market cap of $5.34 million, a price-to-earnings ratio of -1.30 and a beta of 2.17. The stock’s 50-day simple moving average is $4.03 and its two-hundred day simple moving average is $4.01.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.